MeSH tree: D02.455.426.392.368.242.888
The largest real-world study ever conducted on prostate cancer in Brazil analyzed data from 670,205 patients treated through the Brazilian Unified Health System (SUS) over a 16-year period, between 2008 and 2023. Published ...
Jun 1, 2026
0
4
A newly developed targeted radiopharmaceutical treatment can effectively slow tumor growth in pancreatic ductal adenocarcinoma (PDAC), according to new research published in the May issue of The Journal of Nuclear Medicine. ...
May 15, 2026
0
84
Platinum-based chemotherapy is a standard treatment for ovarian cancer, but its effectiveness can be limited in some cases. In some patients, the disease returns or progresses within six months of the last platinum dose, ...
A study published April 10 in The Lancet reports that the anti-PD-1 immunotherapy pembrolizumab (brand name Keytruda) significantly improved overall survival in adults with platinum-resistant ovarian cancer when given as ...
Apr 13, 2026
0
7
New findings from VCU Massey Comprehensive Cancer Center and the VCU Institute of Molecular Medicine (VIMM), published in Pharmacological Research, show that an innovative drug effectively prevents prostate tumors from spreading ...
Apr 2, 2026
0
65
Recent advances in drug discovery research have led to the development of numerous drug candidate compounds with high therapeutic efficacy. However, many of these compounds possess properties that make them difficult to handle, ...
Mar 16, 2026
0
4
A gene called FOXJ1 may drive resistance to taxane chemotherapy during treatment for advanced prostate cancer, according to a new study led by investigators at Weill Cornell Medicine and Beth Israel Deaconess Medical Center. ...
Mar 10, 2026
0
9
A common clinical question for medical oncologists treating metastatic castration-resistant prostate cancer is, should patients who previously received docetaxel and progress on it, reuse docetaxel or switch to cabazitaxel ...
Feb 18, 2026
0
5
Chemotherapy remains one of the most powerful tools in the fight against cancer, yet it often comes with significant long-term side effects that can dramatically affect patients' quality of life. Among the most debilitating ...
Feb 11, 2026
0
45
Triple-negative breast cancer (TNBC) is among the most aggressive types of breast cancer, lacking estrogen, progesterone, and HER2 receptors and thus relying primarily on cytotoxic chemotherapy. Despite initial responsiveness, ...
Jan 7, 2026
0
47
